1
|
Smirnov I, Belogurov A, Friboulet A, Masson P, Gabibov A, Renard PY. Strategies for the selection of catalytic antibodies against organophosphorus nerve agents. Chem Biol Interact 2012; 203:196-201. [PMID: 23123255 DOI: 10.1016/j.cbi.2012.10.011] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2012] [Revised: 10/12/2012] [Accepted: 10/16/2012] [Indexed: 01/25/2023]
Abstract
Among the strategies aimed at biocompatible means for organophosphorus nerve agents neutralization, immunoglobulins have attracted attention in the 1990's and 2000's both for their ability to immobilize the toxicants, but also for their ability to be turned into enzymatically active antibodies known as catalytic antibodies or abzymes (antibodies--enzymes). We will present here a critical review of the successive strategies used for the selection of these nerve agent-hydrolyzing abzymes, based on hapten design, namely antibodies raised against a wide variety of transition state analogs, and eventually the strategies based on anti-idiotypic antibodies and reactibodies.
Collapse
Affiliation(s)
- Ivan Smirnov
- MM Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia
| | | | | | | | | | | |
Collapse
|
2
|
Abstract
Catalytic antibodies (CAbs) occur naturally in healthy individuals where they may form part of the innate immune system, but are preferentially found in those with autoimmune disease. CAbs can also be artificially engineered or elicited by immunizations. Their mechanisms of action include nucleophilic catalysis, induction of conformational strain, coordination with metal ions, and stabilization of transition states. Recent applications of CAbs with clinical significance include the conversion of cocaine to a non-psychoactive form, the degradation of nicotine, activation of prodrugs for targeted chemotherapy, protection from ultraviolet radiation, inhibition of HIV infectivity, and the destruction of aggregates of beta-amyloid implicated in Alzheimer's disease. Artificial CAbs are likely to find increasing applications in research, clinical medicine, diagnostics and manufacturing.
Collapse
Affiliation(s)
- Carl Veith Hanson
- Viral and Rickettsial Disease Laboratory, California Department of Health Services, Richmond, 94804, USA.
| | | | | |
Collapse
|
3
|
Rader C, Turner JM, Heine A, Shabat D, Sinha SC, Wilson IA, Lerner RA, Barbas CF. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. J Mol Biol 2003; 332:889-99. [PMID: 12972259 DOI: 10.1016/s0022-2836(03)00992-6] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Mouse monoclonal antibody 38C2 is the prototype of a new class of catalytic antibodies that were generated by reactive immunization. Through a reactive lysine, 38C2 catalyzes aldol and retro-aldol reactions using the enamine mechanism of natural aldolases. In addition to its remarkable versatility and efficacy in synthetic organic chemistry, 38C2 has been used for the selective activation of prodrugs in vitro and in vivo and thereby emerged as a promising tool for selective chemotherapy. Adding another application with relevance for cancer therapy, designated adaptor immunotherapy, we have recently shown that 38C2 can be chemically programmed to target tumors by formation of a covalent bond of defined stoichiometry with a beta-diketone derivative of an integrin alpha(v)beta(3) targeting RGD peptidomimetic. However, a major limitation for the transition from preclinical to clinical evaluation is the human anti-mouse antibody immune response that mouse 38C2 is likely to elicit in a majority of patients after single administration. Here, we report the humanization of mouse 38C2 based on rational design guided by molecular modeling. In essence, the catalytic center of mouse 38C2, which encompasses a deep hydrophobic pocket with a reactive lysine residue at the bottom, was grafted into a human antibody framework. Humanized 38C2 IgG1 was found to bind to beta-diketone haptens with conserved affinities and revealed strong catalytic activity with identical k(cat) and slightly higher K(M) values compared to the parental mouse antibody. Furthermore, humanized 38C2 IgG1 revealed efficiency in prodrug activation and chemical programming comparable to the parental mouse antibody.
Collapse
Affiliation(s)
- Christoph Rader
- The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Suchkov SV, Gabibov AG, Alekberova ZS, Paleev FN, Gnuchev NV. [Catalytic autoantibodies and their future in practical medicine]. TERAPEVT ARKH 2003; 74:40-5. [PMID: 12469630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
|
5
|
Kakinuma H, Fujii I, Nishi Y. Selective chemotherapeutic strategies using catalytic antibodies: a common pro-moiety for antibody-directed abzyme prodrug therapy. J Immunol Methods 2002; 269:269-81. [PMID: 12379367 DOI: 10.1016/s0022-1759(02)00241-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Prodrug activation by catalytic antibodies (abzymes) conjugated with anti-tumor antibodies, called antibody-directed abzyme prodrug therapy (ADAPT), has been proposed as a strategy for site-specific drug delivery systems for anti-tumor drugs. The delivery of abzymes is achieved by making a bi-specific antibody with a monovalent catalytic antibody and a monovalent binding antibody. To achieve ADAPT, we focused on specific requirements for prodrugs and catalytic antibodies, the stability of the prodrugs against natural enzymes, and the applicability of abzymes for a wide range of prodrugs. Attention was paid to the design of a pro-moiety rather than a parent drug. As a common pro-moiety, we chose vitamin B(6), because the bulky vitamin B(6) esters are relatively stable against hydrolytic enzymes in serum. We have generated catalytic antibodies by immunization of a vitamin B(6) phosphonate transition state analog. The elicited antibodies were found to hydrolyze several anti-cancer and anti-inflammatory prodrugs with the vitamin B(6) pro-moiety. Finally, we evaluated antibody-catalyzed prodrug activation by examining the growth inhibition of human cervical cancer (HeLa) cells with the vitamin B(6) ester of butyric acid. These results suggest that the pro-moiety of vitamin B(6) ester is stable enough to resist natural enzymes in serum and is removed by the tailored catalytic antibodies. The combination of catalytic antibodies and prodrugs masked with vitamin B(6) would allow hydrophobic and highly toxic drugs to be used.
Collapse
Affiliation(s)
- Hiroyuki Kakinuma
- Laboratory of Life Science and Bimolecular Engineering, Japan Tobacco Inc., 6-2 Umegaoka, Aoba-ku, Yokohama 227-8512, Japan
| | | | | |
Collapse
|
6
|
Abstract
Cocaine mediates its reinforcing and toxic actions through a "loss of function" effect at multiple receptors. The difficulties inherent in blocking a pleiotropic blocker pose a great obstacle for the classical receptor-antagonist approach and have contributed to the failure (to date) to devise specific treatments for cocaine overdose and addiction. As an alternative, we have embarked on an investigation of catalytic antibodies, a programmable class of artificial enzyme, as "peripheral blockers" -- agents designed to bind and degrade cocaine in the circulation before it partitions into the central nervous system to exert reinforcing or toxic effects. We synthesized transition-state analogs of cocaine's hydrolysis at its benzoyl ester, immunized mice, prepared hybridomas and developed the first anticocaine catalytic antibodies with the capacity to degrade cocaine to nonreinforcing, nontoxic products. We subsequently identified several families of anticocaine catalytic antibodies and found that the most potent antibody possessed sufficient activity to block cocaine-induced reinforcement, organ dysfunction and sudden death in rodent models of addiction, toxicity and overdose, respectively. With the potential to promote cessation of use, prolong abstinence and provide a treatment for acute overdose, the artificial enzyme approach comprehensively responds to the problem of cocaine.
Collapse
Affiliation(s)
- Shi Xian Deng
- Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, Columbia University, Box 84, 630 W 168th Street, New York, NY 10032, USA
| | | | | |
Collapse
|
7
|
Abstract
Monoclonal antibodies are suitable for therapeutic applications by virtue of their excellent target binding characteristics (specificity, affinity) and long half-life in vivo. Catalytic antibodies (CAbs) potentially represent a new generation of therapeutics with enhanced antigen inactivation capability. Here, we describe prospects for development of therapeutic CAbs to the envelope protein gp120 of HIV. The strategy consists of exploiting the natural tendency of the immune system to synthesize germline-encoded, serine protease-like CAbs. Lupus patients were found to develop antibodies to a conserved component of the CD4 binding site of gp120, potentially offering a means to obtain human antibodies expressing broad reactivity with various HIV strains. Covalently reactive antigen analogs (CRAs) capable of selective recognition of nucleophilic Abs were synthesized and applied to isolate Fv and L chain catalysts from lupus phage repertoires. CRA binding by the recombinant Ab fragments was statistically correlated with catalytic cleavage of model peptide substrates. A peptidyl CRA composed of residues 421-431 with a phosphonate diester moiety at its C terminus was validated as a reagent that combines noncovalent and covalent binding interactions in recognition of a gp120ase L chain. A general challenge in the field is the apparent instability of the catalytic conformation of the Abs. In reference to therapy of HIV infection, assurance is required that the Abs recognize the native conformation of gp120 expressed as a trimer on the virus surface.
Collapse
Affiliation(s)
- Yong-Xin Zhou
- Chemical Immunology and Therapeutics Research Center, Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, 6431 Fannin, Houston, TX 77030, USA
| | | | | | | | | | | |
Collapse
|
8
|
Abstract
Catalytic antibodies have been studied widely, but little is known about their applicability as therapeutic reagents in vivo. Here we report that carbaryl, a widely used broad-spectrum carbamate insecticide that is toxic to animals and humans, is hydrolyzed by polyclonal catalytic antibodies induced in vivo by a phosphate immunogen. To test the efficacy of the in vivo-induced polyclonal antibodies, we immunized mice with the phosphate immunogen and assayed their sensitivity to carbaryl by determining the ED(50) value, the dose that produces lowest-grade tremors in 50% of animals. We found that the ED(50) for immunized mice was 43% higher than that for nonimmunized mice and that this increase in ED(50) probably resulted from the hydrolysis of carbaryl by the catalytic antibodies in vivo. Our results suggest that polyclonal catalytic antibodies can be used as therapeutic reagents in vivo.
Collapse
Affiliation(s)
- Jun Wang
- Department of Immunology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
| | | | | | | |
Collapse
|
9
|
Abstract
In this review, we explore recent developments in the generation of catalytic antibodies and their potential in therapy.
Collapse
Affiliation(s)
- C Tellier
- FRE-CNRS n (degree). 2230 Biocatalyze, Faculté des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 Nantes, France.
| |
Collapse
|
10
|
|
11
|
Abstract
More than ten years have now elapsed since the first reports confirmed that antibodies not only label antigenic targets but can also perform catalytic functions. Much of the initial research in this area focussed on exploring the scope and utility of these biocatalysts both as enzyme mimics and as programmable protein catalysts. However, their potential in the biomedical field has also been probed. This review details the present perspective of catalytic antibodies as new tools for immunotherapy and specifically focuses on their application to prodrug activation and drug inactivation.
Collapse
Affiliation(s)
- L H Jones
- Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, CA 92037, USA
| | | |
Collapse
|
12
|
Abstract
Current treatments for cocaine addiction are not effective. The development of a catalytic monoclonal antibody (mAb) provides a strategy for not only binding, but also degrading cocaine, which offers a broad-based therapy. Hapten design is the central element for programming antibody catalysis. The characteristics of the linker used in classic transition-state analogue phosphonate haptens were shown to be important for obtaining mAbs that hydrolyze the benzoate ester of cocaine.
Collapse
Affiliation(s)
- M Matsushita
- The Scripps Research Institute and the Skaggs Institute for Chemical Biology, Department of Chemistry, La Jolla, CA 92037, USA
| | | | | | | | | | | |
Collapse
|
13
|
Abstract
A reagent capable of detecting and selectively destroying tumor cells while leaving healthy cells intact would be a powerful tool for cancer therapy. This concept of the magic bullet has been approached by a number of strategies. Here we present a recent approach based on catalytic antibodies.
Collapse
Affiliation(s)
- C Rader
- Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | |
Collapse
|
14
|
Sparenborg S, Vocci F, Zukin S. Peripheral cocaine-blocking agents: new medications for cocaine dependence. An introduction to immunological and enzymatic approaches to treating cocaine dependence reported by Fox, Gorelick and Cohen in the immediately succeeding articles (see pages 153-174). Drug Alcohol Depend 1997; 48:149-51. [PMID: 9449012 DOI: 10.1016/s0376-8716(97)00072-0] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- S Sparenborg
- Medications Development Division, National Institute on Drug Abuse, National Institutes of Health, Rockville, MD 20857, USA.
| | | | | |
Collapse
|
15
|
Affiliation(s)
- A Persidis
- Argonex Inc., Charlottesville, VA 22901, USA
| |
Collapse
|
16
|
Affiliation(s)
- D W Landry
- Columbia University College of Physicians and Surgeons, USA
| |
Collapse
|
17
|
Abstract
Cocaine reinforces its self-administration in relation to the magnitude of and rate of rise to the peak serum concentration of the drug. Catalytic antibodies are artificial enzymes which could reduce serum cocaine concentrations, deprive the abuser of cocaine's reinforcing effect and thus favor extinction of the addiction. Catalytic antibodies are elicited by immunization with a stable analog of a transition-state for a chemical reaction. Through our new method for synthesizing phosphonate monoesters, we constructed several phosphonate-based transition-state analogs of cocaine hydrolysis. Using these analogs, monoclonal antibodies were elicited and, thus far, nine anti-analog antibodies with hydrolytic activity against cocaine have been identified, cloned and studied. The activity of one of these antibodies, 15A10, is sufficient to commence preclinical studies.
Collapse
Affiliation(s)
- D W Landry
- Department of Medicine, Columbia University, College of Physicians & Surgeons, New York, NY 10032, USA
| | | |
Collapse
|
18
|
Amital H, Tur-Kaspa I, Tashma Z, Hendler I, Shoenfeld Y. Catalytic antibodies: generation, nature, and possible role as chemical warfare scavengers. Mil Med 1996; 161:7-10. [PMID: 11082742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
Abstract
Nearly three decades have passed since the idea was proposed that antibodies may provide catalytic activity as enzymes. Since then the term "catalytic antibodies" has gained more and more popularity. Numerous antibodies enhancing the rate of reactions have been described. This review will address the basic biological considerations involved in the genesis of catalytic antibodies and explore their possible role in the future providing protection in chemical warfare.
Collapse
Affiliation(s)
- H Amital
- Department of Medicine B, Sheba Medical Center, Tel-Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Israel
| | | | | | | | | |
Collapse
|
19
|
Amital H, Tur-Caspa I, Hendler I, Shoenfeld Y. [Catalytic antibody-structure and possible applications]. Harefuah 1995; 128:295-8. [PMID: 7744352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
20
|
Abstract
Catalytic antibodies both label antigenic targets and perform enzymatic functions. Since the conceivable specificities are virtually limitless, the potential of such tools is great. They can, for example, be engineered to destroy specific pathogens or tumor cells, to protect normal cells from chemotoxicity, or to activate prodrugs at the target site.
Collapse
Affiliation(s)
- R A Lerner
- Scripps Research Institute, La Jolla, Calif
| |
Collapse
|
21
|
Abstract
Immunization with a phosphonate monoester transition-state analog of cocaine provided monoclonal antibodies capable of catalyzing the hydrolysis of the cocaine benzoyl ester group. An assay for the degradation of radiolabeled cocaine identified active enzymes. Benzoyl esterolysis yields ecgonine methyl ester and benzoic acid, fragments devoid of cocaine's stimulant activity. Passive immunization with such an artificial enzyme could provide a treatment for dependence by blunting reinforcement.
Collapse
Affiliation(s)
- D W Landry
- Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032
| | | | | | | | | |
Collapse
|
22
|
|